Recent Updates
Recently added Catalysts
VKTX Neutral Sentiment

Obesity Impact on Incidence of Chronic Comorbid Conditions

Key Takeaway: The article provides an overview of VKTX's management, board of directors, and pipeline products, including VK2735, VK3019, VK2809, VK0214, and VK5211. It also includes information on investor relations, stock information, and corporate governance. However, it lacks specific details about the impact of obesity on chronic comorbid conditions.
Price reaction · baseline $28.3 (2025-05-12 close) · hit pre-market · clean, no other VKTX news in the window
day 0 close · peak
-2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

• About Management Board of Directors Careers
• Pipeline Overview VK2735 VK3019 VK2809 VK0214 VK5211 Publications
• Investors Overview Stock Information Stock Chart Historical Price Lookup News & Events Press Releases Webcasts SEC Filings Analyst Coverage Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition Shareholder Services Information Request E-mail Alerts Investor Relations Contacts Corporate Presentation
• Contact
• Management
• Board of Directors
• Careers
• Overview
• VK2735
• VK3019
• VK2809
• VK0214
• VK5211
• Publications
• Overview
• Stock Information Stock Chart Historical Price Lookup
• News & Events Press Releases Webcasts
• SEC Filings
• Analyst Coverage
• Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition
• Shareholder Services Information Request E-mail Alerts Investor Relations Contacts
• Corporate Presentation
• Stock Chart
• Historical Price Lookup
• Press Releases
• Webcasts
• Governance Highlights
• Mangement
• Board of Directors
• Committee Composition
• Information Request
• E-mail Alerts
• Investor Relations Contacts
Last updated: May 13, 2025